ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,398,172, issued on Aug. 26, was assigned to Caris Science Inc. (Irving, Texas).
"Therapeutic oligonucleotides" was invented by Heather O'Neill (Mesa, Ariz.), Gunter Mayer (Bonn, Germany), Mark Miglarese (Phoenix) and David Spetzler (Paradise Valley, Ariz.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RP...